Ethyl 7-hydroxypyrazolo[1,5-a]pyrimidine-6-carboxylate | 43024-61-9

• 物质功能分类: 医药中间体 - 嘧啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: Ethyl 7-hydroxypyrazolo[1,5-a]pyrimidine-6-carboxylate
• 英文别名: 6-ethoxycarbonyl-7-hydroxypyrazolo<1,5-a>pyrimidine；6-carbethoxy-7-hydroxypyrazolo<1,5-a>pyrimidine；7-oxo-4,7-dihydro-pyrazolo[1,5-a]pyrimidine-6-carboxylic acid ethyl ester；7-hydroxy-pyrazolo[1,5-a]pyrimidine-6-carboxylic acid ethyl ester；7-Hydroxy-pyrazolo<1,5-a>pyrimidin-carbonsaeure-(6)-ethylester；6-Carbethoxy-7-hydroxypyrazolo<1,5-a>-pyrimidin
• CAS: 43024-61-9
• 化学式: C₉H₉N₃O₃
• 分子量: 207.189
• InChiKey: NVDWGKJXHWMJEU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.61
• 重原子数：
  15.0
• 可旋转键数：
  2.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  76.72
• 氢给体数：
  1.0
• 氢受体数：
  6.0

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H320,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Ethyl 7-hydroxypyrazolo[1,5-a]pyrimidine-6-carboxylate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Ethyl 7-hydroxypyrazolo[1,5-a]pyrimidine-6-carboxylate
CAS number: 43024-61-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C9H9N3O3
Molecular weight: 207.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  Ethyl 7-hydroxypyrazolo[1,5-a]pyrimidine-6-carboxylate 在 sodium carbonate 、 N,N-二乙基苯胺 、 三氯氧磷 作用下， 以 水 为溶剂， 反应 5.0h， 生成 N-(6-carbethoxypyrazolo<1,5-a>pyrimidin-7-yl)clycine
  参考文献：
  名称：

  6-乙氧基-和6-乙氧基-3,7-二取代-吡唑并[1,5-a]嘧啶及相关衍生物作为腺苷环3'，5'-磷酸磷酸二酯酶抑制剂的合成及酶活性。

  摘要：

  已经制备了许多3，7-二取代的6-碳乙氧基吡唑并[1，5-a]嘧啶和3，7-二取代的6-乙氧基吡唑并[1，5-a]嘧啶，并将其评估为腺苷环3'，5'。 -磷酸（cAMP）磷酸二酯酶（PDE）抑制剂与从牛肉心，兔肺和肾脏制剂中分离的低Km酶相比。根据组织来源，发现结果是茶碱的功效是PDE抑制剂的茶碱的0.5至13倍。这些PDE抑制剂中的许多在不同的动物系统中均表现出显着的生理作用，这表明应该有可能在各种组织中获得选择性的PDE抑制。发现这些杂环中的几种在体外抑制ADP诱导的血小板聚集方面优于腺苷。

  DOI：

  10.1021/jm00345a009
• 作为产物：
  描述：

  3-氨基吡唑 、 乙氧基甲叉丙二酸二乙酯 以 溶剂黄146 为溶剂， 生成 Ethyl 7-hydroxypyrazolo[1,5-a]pyrimidine-6-carboxylate
  参考文献：
  名称：

  Penicillins

  摘要：

  一类α-(杂环羰基氨基) 青霉素类药物，其中酰基部分的杂环基团是具有氮原子的融合双环环的，在桥位显示出良好的抗菌活性。

  公开号：

  US04081545A1

文献信息

• 3-Aminocarbonyl-substituted fused pyrazolo-derivatives as protein kinase modulators
  申请人：Novartis AG

  公开号：EP1918291A1

  公开（公告）日：2008-05-07

  The present invention relates to pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds of formula I or pharmaceutically acceptable salts thereof and their use for the treatment of protein kinase modulation responsive diseases.

  本发明涉及式I的吡唑并[1,5-a]嘧啶-3-羧酸化合物或其药用盐，以及它们用于治疗蛋白激酶调节响应性疾病的用途。
• CHEMOKINE RECEPTOR ACTIVITY REGULATOR
  申请人：Yamamoto Keisuke

  公开号：US20140221340A1

  公开（公告）日：2014-08-07

  The invention provides a chemokine receptor activity modulator containing a pyrazolopyrimidine derivative represented by the formula (I) wherein R 1 , R 2 , R 3 , and R 4 are as described herein.

  该发明提供了一种包含由式(I)表示的吡唑吡咯啉衍生物的趋化因子受体活性调节剂，其中R1、R2、R3和R4如本文所述。
• Pyrazolo[1,5-a]pyrimidine-3-carboxylic acid compounds as protein kinase inhibitors
  申请人：Imbach Patricia

  公开号：US20100069395A1

  公开（公告）日：2010-03-18

  Compounds of formula wherein the residues have various meanings, their pharmaceutical use, pharmaceutical compositions comprising such compounds and methods for preparation and use for the treatment of protein kinase modulation responsive disorders.

  该文献涉及公式中残基具有不同含义的化合物，其在制药学上的用途，包括这些化合物的制药组合物和用于治疗蛋白激酶调节反应性疾病的制备和使用方法。
• PYRAZOLOPYRIMIDINE DERIVATIVE
  申请人：Yamamoto Keisuke

  公开号：US20130102620A1

  公开（公告）日：2013-04-25

  The invention provides a pyrazolopyrimidine derivative of formula (I), wherein, for example, R 1 represents —NR 1a R 1b (wherein R 1a and R 1b are the same or different and each is a hydrogen atom or aralkyl), R 2 represents formula (Ya) [wherein k and m each represents an integer of 0-2, n represents an integer of 0-4, L represents a single bond, R 5 represents halogen, R 6 represents aryl, X represents —CR 8 (wherein R 8 represents a hydrogen atom), and R 7 represents a hydrogen], R 3 represents —SO 2 R 13a [wherein R 13a represents lower alkoxy, —NR 13d C(═O)R 13e (wherein R 13d represents a hydrogen atom, and R 13e represents lower alkyl)], and R 4 represents a hydrogen atom, or a pharmaceutically acceptable salt thereof. The invention also provides a medicament containing the pyrazolopyrimidine derivative, as well as a method of using the pyrazolopyrimidine derivative to prevent and/or treat skin diseases.

  该发明提供了一种式为(I)的吡唑嘧啶衍生物，其中，例如，R1代表—NR1aR1b（其中R1a和R1b相同或不同，每个都是氢原子或芳基烷基），R2代表式(Ya) [其中k和m分别表示0-2的整数，n表示0-4的整数，L表示单键，R5表示卤素，R6表示芳基，X表示—CR8（其中R8表示氢原子），R7表示氢]，R3表示—SO2R13a [其中R13a表示较低的烷氧基，—NR13dC（═O）R13e（其中R13d表示氢原子，R13e表示较低的烷基）]，R4表示氢原子，或其药学上可接受的盐。该发明还提供了含有该吡唑嘧啶衍生物的药物，以及使用该吡唑嘧啶衍生物预防和/或治疗皮肤疾病的方法。
• Pyrazolopyrimidine derivative
  申请人：Yamamoto Keisuke

  公开号：US08815874B2

  公开（公告）日：2014-08-26

  The invention provides a pyrazolopyrimidine derivative of formula (I), wherein, for example, R1 represents —NR1aR1b (wherein R1a and R1b are the same or different and each is a hydrogen atom or aralkyl), R2 represents formula (Ya) [wherein k and m each represents an integer of 0-2, n represents an integer of 0-4, L represents a single bond, R5 represents halogen, R6 represents aryl, X represents —CR8 (wherein R8 represents a hydrogen atom), and R7 represents a hydrogen], R3 represents —SO2R13a [wherein R13a represents lower alkoxy, —NR13dC(═O)R13e (wherein R13d represents a hydrogen atom, and R13e represents lower alkyl)], and R4 represents a hydrogen atom, or a pharmaceutically acceptable salt thereof. The invention also provides a medicament containing the pyrazolopyrimidine derivative, as well as a method of using the pyrazolopyrimidine derivative to prevent and/or treat skin diseases.

  本发明提供一种式（I）的吡唑嘧啶衍生物，其中，例如，R1代表—NR1aR1b（其中R1a和R1b相同或不同，且每个都是氢原子或芳基烷基），R2代表式（Ya）[其中k和m分别表示0-2的整数，n表示0-4的整数，L表示单键，R5表示卤素，R6表示芳基，X表示—CR8（其中R8表示氢原子），R7表示氢]，R3表示—SO2R13a [其中R13a表示低碳酰氧基，—NR13dC（═O）R13e（其中R13d表示氢原子，R13e表示低烷基）]，R4表示氢原子，或其药学上可接受的盐。本发明还提供一种含有该吡唑嘧啶衍生物的药物，以及使用该吡唑嘧啶衍生物预防和/或治疗皮肤疾病的方法。